Cover Image

Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand

Objective: This study aimed to investigate the clinical impact of HLA-B*15:02 pharmacogenomics (PGx) testing before carbamazepine (CBZ)/oxcarbazepine (OXC) prescriptions and to determine whether this PGx testing was associated with the reduction of CBZ/OXC-induced cutaneous adverse drug reactions (C...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kanyawan Tiwattanon (Author), Shobana John (Author), Napatrupron Koomdee (Author), Pimonpan Jinda (Author), Jiratha Rachanakul (Author), Thawinee Jantararoungtong (Author), Nutthan Nuntharadthanaphong (Author), Chiraphat Kloypan (Author), Mohitosh Biswas (Author), Apisit Boongird (Author), Chonlaphat Sukasem (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand
by: Napatrupron Koomdee, et al.
Published: (2022)

A Comprehensive Review of <i>HLA</i> and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine
by: Chiraphat Kloypan, et al.
Published: (2021)

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis
by: Chalirmporn Atasilp, et al.
Published: (2022)

Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications
by: Mohitosh Biswas, et al.
Published: (2024)

HLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand
by: Chonlaphat Sukasem, et al.
Published: (2016)

Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics
by: Patompong Satapornpong, et al.
Published: (2020)

Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
by: Mohitosh Biswas, et al.
Published: (2022)

Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis
by: Mohitosh Biswas, et al.
Published: (2022)

Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics
by: Therdpong Tempark, et al.
Published: (2022)

Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population
by: Napatrupron Koomdee, et al.
Published: (2017)

Influence of pharmacogenomic polymorphisms on allopurinol-induced cutaneous adverse drug reactions in Thai patients
by: Gaidganok Sornsamdang, et al.
Published: (2024)

Effect of <i>GSTA1</i> Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
by: Ai-Hoc Nguyen, et al.
Published: (2022)

The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam
by: Ai-Hoc Nguyen, et al.
Published: (2023)

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
by: Sumonrat Chuwongwattana, et al.
Published: (2020)

The association of CYP2C19 LoF alleles with adverse clinical outcomes in stroke patients taking clopidogrel: An updated meta‐analysis
by: Mohitosh Biswas, et al.
Published: (2024)

CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
by: Teerapat Majam, et al.
Published: (2023)

Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population
by: Chalirmporn Atasilp, et al.
Published: (2022)

Editorial: Brief research reports in pharmacogenetics and pharmacogenomics: 2022
by: Francesco Sessa, et al.
Published: (2023)

Editorial: Pharmacogenomics and ethnicity: Prevalence and clinical significance of pharmacogenomic biomarkers in indigenous and other populations
by: George P. Patrinos, et al.
Published: (2023)

Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of SLCO1B1 in the Thai Population
by: Chalitpon Na nakorn, et al.
Published: (2020)

Molecular identification of HLA‐B75 serotype markers by qPCR: A more inclusive pharmacogenetic approach before carbamazepine prescription
by: Kanoot Jaruthamsophon, et al.
Published: (2024)

Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder
by: Yaowaluck Hongkaew, et al.
Published: (2021)

Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors
by: Natchaya Vanwong, et al.
Published: (2020)

Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations
by: Kanyarat Khaeso, et al.
Published: (2021)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
by: Sukasem C, et al.
Published: (2013)

Pharmacogenomic study reveals new variants of drug metabolizing enzyme and transporter genes associated with steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in Thai autism spectrum disorder patients
by: Sadeep Medhasi, et al.
Published: (2016)

Influence of SULT1A1&ast;2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients
by: Chamnanphon M, et al.
Published: (2021)

A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data
by: Shobana John, et al.
Published: (2024)

Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population
by: Shobana John, et al.
Published: (2024)

The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
by: Bushyakanist A, et al.
Published: (2015)

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
by: Damronglerd P, et al.
Published: (2015)

CYP2D6 polymorphisms and their influence on risperidone treatment
by: Puangpetch A, et al.
Published: (2016)

Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report
by: Tan-kam T, et al.
Published: (2013)

Pharmacokinetics of mitragynine in man
by: Trakulsrichai S, et al.
Published: (2015)

Risk-Benefits of Oxcarbazepine vs Carbamazepine
by: J Gordon Millichap
Published: (2004)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
by: Sirachainan E, et al.
Published: (2012)

Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV
by: Turongkaravee S, et al.
Published: (2022)

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2013)

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin
by: Srisawasdi P, et al.
Published: (2021)

Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia
by: Puangpetch A, et al.
Published: (2019)